drugset / Trial / NCT00522821
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
RandomizedCrossoverOpen-labelPrevention
Summary
There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.
Timeline
- Start
- 2007-11
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 600 mg/kg | Intravenous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 800 mg/kg | Intravenous |
| Subject | Sulfamethoxazole | Small molecule | 20 mg/kg | — |
| Subject | Sulfamethoxazole | Small molecule | 800 mg | — |
| Subject | Trimethoprim | Small molecule | 4 mg/kg | — |
| Subject | Trimethoprim | Small molecule | 160 mg | — |
| Subject | azitromycine | Unknown | — | — |
| Background | folic acid | Other / unclassified | 5 mg | — |